Physician profile
Thomas Bayer
NPI 1710276316
$519.05
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2024: $57.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.01 | 2019 | |
| Novo Nordisk INC | $67.80 | 2019 | |
| Glaxosmithkline, LLC. | $63.90 | 2019 | |
| Neurocrine Biosciences, INC. | $57.44 | 2024 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $56.76 | 2019 | |
| Allergan, INC. | $41.07 | 2019 | |
| Astellas Pharma US INC | $31.68 | 2019 | |
| Lilly USA, LLC | $29.90 | 2019 | |
| Sanofi Pasteur INC. | $17.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.34 | 2019 | |
| Pfizer INC. | $14.55 | 2019 | |
| Amarin Pharma, INC. | $14.53 | 2019 | |
| Abbott Laboratories | $14.25 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.